Read the new article “Brief recommendations on the management of adult patients with FH during the COVID-19 pandemic”
More → Category: News, PublicationsRead the new article “Brief recommendations on the management of adult patients with FH during the COVID-19 pandemic”
More → Category: News, PublicationsApproximately 30 million people worldwide suffer from FH. These patients have an increased risk of atherosclerotic CV disease and its atherothrombotic complications already in middle age. It is likely that COVID-19 further increases their cardiovascular risk, both during infection and after recovery. We advise continued use of treatment for the severe hypercholesterolaemia observed in these patients.
More → Category: News, Publications“The Impact of the International Cooperation On FH Screening and Treatment: Results from the ScreenPro FH Project” was published in the Current Atherosclerosis Reports in September 2019.
More → Category: News, PublicationsAuthors: R. Ceska, G. Latkovskis, M. Ezhov, T. Freiberger, K. Lalic, O. Mitchenko, G. Paragh, Z. Petrulioniene, B. Pojskic, K Raslova, A. B. Shek, B. Vohnout, T. Altschmiedova, T. Todorovova
Abstract: Purpose of Review Familial hypercholesterolemia (FH) is often perceived and described as underdiagnosed and undertreated,though effective treatment of FH is available. Owing to the mentioned facts, it is ever more imperative to screen and treat FHpatients. Subsequent to the identification of patients, the project focuses on the improvement of their prognoses. The ScreenProFH project was established as a functional international network for the diagnosis, screening, and treatment of FH. Individualcountries were assigned goals, e.g., to define the actual situation and available treatment. With “central support,” more centersand countries participated in the project. Subsequently, individual countries reported the results at the beginning and end of theproject. Collected data were statistically evaluated.Recent Findings The increasing number of patients in databases, from 7500 in 2014 to 25,347 in 2018, demonstrates theimprovement in overall effectiveness, aswell as an increase in the number of centers from 70 to 252. Before all, LDL-C decreasedby 41.5% and total cholesterol by 32.3%. As data from all countries and patients were not available at the time of the analysis,only those results from 10 countries and 5585 patients at the beginning of the project and at the time of writing are included.Summary Our data are quite positive. However, our results have only limited validity. Our patients are far from the target levelsof LDL-C. The situation can be improved with the introduction of new therapy, PCSK9-i, evolocumab, and alirocumab.International cooperation improved the screening of FH and finally led to an improvement in cardiovascular risk.
The article is published open access and is freely accessible to everyone. You can find it HERE.
PDF version of the article is ready to download HERE.
More → Category: PublicationsAuthors: R. Ceska, T. Freiberger, M. Vaclova, T. Aleksicova,
L. Votavova, M. Vrablik
Summary:
This article describes the evolution of our understanding of familial hypercholesterolemia (FH) in the Central, Eastern, and Southern Europe (CESE) region, and the dissemination of this understanding to other countries. Using the ScreenPro FH project as an example, we would like to illustrate the progression from national objectives, to regional networking and, finally, to international collaboration via the Familial Hypercholesterolemia Studies Collaboration (FHSC) project under the leadership of the European Atherosclerosis Society (EAS).